commitment
For
over 50 years, Baxter has been a trusted leader in developing state-of-the-art
plasma therapeutics to help patients lead healthier, more active lives.
We are dedicated to continued research that helps us make new therapies
available to those in need.
For people with primary immunodeficiency (PI), therapy with intravenous immunoglobulin (IVIG) is a standard of care. At Baxter, we are committed to raising that standard by enhancing safety, efficacy, and convenience and by working to minimize side effects.
Visit immunedisease.com for information about all the ways Baxter is working to support the PI community.
Please see Important Safety Information and Full Prescribing Information for GAMMAGARD LIQUID.